AFP and neoplasm: All this evidence supports that, as already proposed by EASL in 2018, composite criteria that consider surrogates of tumour biology—among which AFP is the most relevant—and response to neoadjuvant treatments in combination with tumour size and number of nodules, are likely to replace conventional criteria for defining transplantability [8].